Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is a key non-receptor protein tyrosine phosphatase.
• It acts as a central regulator for critical oncogenic signaling pathways, including Jak/STAT, PI3K/AKT, RAS/Raf/MAPK, and PD-1/PD-L1.
• Dysregulation of SHP2 is implicated in various genetic developmental disorders and cancers.

Purpose of the Study:

• To review the physiological and biological functions of SHP2.
• To discuss the recent advancements in the development of SHP2 inhibitors, focusing on both catalytic and allosteric approaches.

Main Methods:

• Literature review of SHP2's role in cellular signaling and disease.
• Analysis of the development strategies for SHP2 inhibitors, including historical catalytic site-targeted approaches and recent allosteric inhibitors.
• Summary of clinical trial progress for SHP2-targeting drugs.

Main Results:

• Catalytic site inhibitors for SHP2 have not progressed to clinical development.
• Allosteric inhibitors targeting the non-catalytic site of SHP2 represent a promising therapeutic strategy.
• Four SHP2 allosteric inhibitors have advanced into clinical trials for solid tumor treatment.

Conclusions:

• SHP2 is a significant therapeutic target in oncology due to its role in multiple cancer-promoting pathways.
• Allosteric inhibition offers a novel and potentially more effective approach to targeting SHP2 compared to catalytic inhibition.
• The progression of SHP2 allosteric inhibitors into clinical trials signifies a major step forward in cancer therapy development.